Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma
{{output}}
Background: Clinical data on chimeric antigen receptor (CAR) T-cell therapy in Japanese patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) are limited. This study evaluated the safety and long... ...
